Top 5 Papers
#1
Source: Signal Transduction and Targeted Therapy | Authors: Li SH, Wei W, et al. (multicenter, NCT04961918) | Published: May 15, 2026
Score: 10/20 — Base 6 (high-impact translational journal, IF ~39, arguably Nature Communications tier) + Phase II (+2) + survival benefit OS + PFS (+2) = 10
Prospective single-arm Phase II in 40 patients with unresectable hepatocellular carcinoma combining hepatic arterial infusion FOLFOX with systemic lenvatinib and the PD-L1 inhibitor durvalumab. Median PFS 15.8 months (95% CI 8.3–23.3), ORR 75.0% (9 CR/pCR + 21 PR), DCR 95.0%, 1-year OS 97.5%, 2-year OS 94.0%. Seven patients (17.5%) underwent R0 conversion surgery, three with pathologic complete response. Grade 3 toxicities limited to ALT elevation and thrombocytopenia (5% each), no grade 4 events. The triple combination delivers the highest reported response rate and conversion rate to date in this regimen class for uHCC.
Post angle: Hepatic arterial infusion is finally getting the systemic backbone it needed — randomized confirmation is the obvious next step. #HCC #HAIC #LiverCancer #GIOnc
#2
Source: European Journal of Cancer | Authors: Hofheinz RD, Al-Batran SE, et al. (AIO-KRK-0117/IKF 629, multicenter, NCT03986294) | Published: March 24, 2026
Score: 9/20 — Base 5 + Phase II RCT (+2) + PFS survival benefit (+2) = 9
Randomized Phase II in 120 frail elderly mCRC patients (82% frail by G8/Balducci, median age 78.5 years) comparing dose-reduced mFOLFOX7 against aflibercept + 5-FU/LV as first-line therapy. Primary endpoint PFS@6 months: 68% (mFOLFOX7) vs 46% (aflibercept arm). Median PFS 7.9 vs 5.5 months; median OS 20.4 vs 19.0 months; ORR 47% vs 22%. Grade ≥3 hypertension reached 41% and SAEs 17% in the aflibercept arm versus 5% in the FOLFOX arm. The trial settles a long-standing question for the geriatric-oncology community: in fit-but-older patients, dose-reduced oxaliplatin doublet remains the better backbone — VEGF-trap with 5-FU alone trades efficacy for toxicity without compensating gains.
Post angle: Frail ≠ no chemo. Dose-reduced mFOLFOX7 still wins for fit-but-older mCRC patients — and aflibercept+5FU comes with a real toxicity cost without the efficacy. #CRC #GeriatricOncology #GIOnc
#3
Source: JAMA Oncology | Authors: Ding J, Hoffmeister M, et al. (German Cancer Research Center, Heidelberg) | Published: May 14, 2026
Score: 9/20 — Base 7 (Tier-1 JAMA Oncology) + real-world cohort (+1) + biomarker-guided precision prevention (+1) = 9. Tier-1 safety-net paper.
Prospective UK Biobank cohort of 290,645 cancer-free adults with a median 11.7-year follow-up and 1,187 incident pancreatic cancers. A 7-component modifiable-risk score (MRS: smoking, alcohol, diet, physical inactivity, obesity, diabetes, pancreatitis) and a validated polygenic risk score were analyzed by age strata. The MRS was much more strongly associated with PDAC in adults under 60 (HR 1.69 per 1-point MRS) than in those ≥70 (HR 1.20; P-interaction <0.001). Among the <60 group, the absolute standardized cumulative incidence (SCI) ranged from 38.2 per 100,000 in high-PRS/low-MRS individuals to 92.2 per 100,000 in high-PRS/high-MRS individuals — a 6.1-fold larger absolute risk gap than in the low-PRS group. The data reframe precision prevention: lifestyle modification yields the greatest absolute benefit when targeted at genetically high-risk young adults.
Post angle: Precision prevention is the under-told story in PDAC. Lifestyle isn't optional for genetically high-risk young adults — and the absolute risk reduction is 6× what you'd see in lower-PRS peers. #PDAC #PancreaticCancer #Prevention #GIOnc
#4
Source: ESMO Open | Authors: Lee CK, Rha SY, et al. (Yonsei Cancer Center, Seoul) | Published: May 13, 2026
Score: 8/20 — Base 5 + retrospective real-world (+1) + biomarker-guided precision (+1) + KOL engagement @DraMartinezLago (+1) = 8
Retrospective analysis of 2,007 stage IV gastric/GEJ adenocarcinoma patients (2015–2022) plus a 777-patient NGS subcohort. HER2 status distribution: HER2-high 18.5%, HER2-low 26.1%, HER2-null 55.4%. Median OS by HER2 status was 17.2 months (high), 13.4 months (low) and 14.5 months (null); HER2-low cancers were therefore not simply diluted HER2-null disease. ICI-containing first-line combinations conferred greater OS benefit in HER2-low than in HER2-null patients. NGS profiling showed HER2-low tumors were enriched for angiogenesis-pathway alterations (FGF/FGFR, VEGF/VEGFR, PDGFR) that tracked with worse survival. The findings provide the real-world genomic substrate for the trastuzumab-deruxtecan-and-beyond ADC era in gastric cancer — HER2-low is a biology, not just a regulatory category.
Post angle: HER2-low gastric is a real, actionable biology — ICIs already help more there than in HER2-null, and the angiogenesis-pathway enrichment hints at where the next combinations should go. #GastricCancer #HER2 #PrecisionOncology #GIOnc
#5
Source: Journal of Robotic Surgery | Authors: Sabah T, Mah HK, et al. (University Health Network Toronto, multicenter) | Published: May 14, 2026
Score: 7/20 — Base 5 + meta-analysis (+2) = 7
Systematic review and meta-analysis of 64 comparative studies enrolling 15,790 patients (5,723 robotic, 10,067 laparoscopic distal pancreatectomy). Robotic distal pancreatectomy was associated with significantly lower estimated blood loss (WMD −52.0 mL), fewer open conversions (RR 0.49), fewer unplanned splenectomies (RR 0.59) and shorter length of stay (−0.57 days). Operative time was 24 minutes longer with the robotic approach. R0 resection rate, lymph node yield, postoperative pancreatic fistula and overall morbidity were comparable. In the PDAC-only subgroup, oncologic outcomes (R0, nodal yield) were equivalent. The paper is a natural companion to last week's robotic-vs-laparoscopic low anterior resection meta-analysis — the surgical literature continues to favor robotics across major GI resections.
Post angle: Distal pancreatectomy is one more procedure where the robotics literature has tipped — lower blood loss, fewer conversions, equivalent oncology. #PancreaticCancer #Surgery #RoboticSurgery #GIOnc
Additional Papers of Interest
-
European Journal of Cancer — cfDNA + ML across 109 studies (liver n=29, CRC n=28, PDAC n=16, esophageal n=12, gastric n=9): sensitivity 72–92% for stage I–III, specificity 94–99%; neural networks (90%), random forest (86%) and fragmentomics (86%) top performers.
-
European Journal of Cancer — randomized 120-patient trial (Amsterdam + Verona + Barcelona + Vienna + Maastricht): mPFS 2.2 vs 3.3 mo (HR 1.27, p=0.26), mOS 6.0 vs 9.1 mo (HR 1.47, p=0.054). S-1 does not replace 5-FU/LV as the fluoropyrimidine partner of nal-IRI in 2L PDAC.
-
International Journal of Cancer — 15 RCTs (7 ESCC, 8 GEA). ESCC: men OS HR 0.70 (p<0.00001), women HR 0.81 (p=0.14); GEA: both sexes benefit (HR 0.78 men, 0.82 women). No formal sex-treatment interaction (p=0.31 ESCC, p=0.38 GEA) — but the numerical attenuation in female ESCC patients warrants continued reporting.
-
Supportive Care in Cancer — preoperative exercise reduced postoperative ileus incidence (OR 0.56) and shortened time to first flatus (SMD −0.41); postoperative exercise-only interventions did NOT independently improve bowel recovery (SMD −0.31, n.s.). The actionable signal sits prehab-side.
Back to all digests